X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

BDTX

Closed

Black Diamond Therapeutics Inc

2.48
0.00 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.48
Day's Range: 2.435 - 2.62
Send
When Written:
 
1.89
Black Diamond Therapeutics Inc is a biotechnology company that focuses on developing precision medicines for cancer treatment. The company utilizes its proprietary platform, Mutation-Allostery-Pharmacology, to identify and develop small molecule drugs that target oncogenic mutations. The platform enables the company to design drugs that selectively bind to and inhibit the activity of mutated proteins, while sparing normal cells.

The company's lead product candidate, BDTX-189, is a small molecule inhibitor designed to target multiple mutations in the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients. The company is also developing other product candidates targeting different oncogenic mutations, including KRAS and BRAF.

Black Diamond Therapeutics Inc was founded in 2014 and is headquartered in Cambridge, Massachusetts. The company went public in January 2020 and is listed on the Nasdaq under the ticker symbol "BDTX".

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X